We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 542.00 | 4.77% | 11,894.00 | 11,892.00 | 11,896.00 | 12,086.00 | 11,850.00 | 11,890.00 | 1,361,786 | 14:06:40 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.03 | 184.78B |
From Apr 2019 to Apr 2024
By Sabela Ojea
AstraZeneca PLC said Wednesday that its Tagrisso medicine has been approved in China for the treatment of early lung cancer.
The U.K.-based pharmaceutical giant said Tagrisso is the first such drug to have received approval in China, as well as the only one to have shown efficacy against the disease in a global trial.
The FTSE 100 company added that the approval is based on the positive results coming from the Adaura Phase 3 trial, where Tagrisso was proven to reduce the risk of disease recurrence or death by 80%.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
April 14, 2021 02:33 ET (06:33 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
